Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor

Simona Caporali(Istituto Dermopatico dell'Immacolata), Stefania D’Atri(Istituto Dermopatico dell'Immacolata)
International Journal of Oncology
June 30, 2016
Cited by 72


Related Papers